Condition: Non Small Cell Lung Cancer · Sponsor: OncoC4, Inc.
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once every 21 days, for up to 17 cycles in approximately one year.
This description comes directly from the study's public registry record.
Pan Zheng, MD, PhD · 2027516823 · pzheng@oncoc4.com
Always discuss trial participation with your own doctor first.
| XCancer/Dothan Hematology & Oncology - 1114 | Dothan, Alabama, United States | Recruiting |
| Genesis Cancer and Blood Institute - 1123 | Russellville, Arkansas, United States | Recruiting |
| The Oncology Institute (TOI) Clinical Research - 1109 | Cerritos, California, United States | Recruiting |
| Emad Ibrahim MD Inc. - 1147 | Redlands, California, United States | Recruiting |
| UC Davis Comprehensive Cancer Center - 1103 | Sacramento, California, United States | Recruiting |
| Bass Medical Group - 1155 | Walnut Creek, California, United States | Recruiting |
| Nuvance Health - 1118 | Norwalk, Connecticut, United States | Recruiting |
| D&H Cancer Research Center LLC - 1153 | Margate, Florida, United States | Recruiting |
| Ocala Oncology Center PL - 1102 | Ocala, Florida, United States | Recruiting |
| AdventHealth Cancer Institute - 1105 | Orlando, Florida, United States | Recruiting |
| Orlando Health - 1130 | Orlando, Florida, United States | Recruiting |
| Florida Cancer Specialists -South - 1126 | Sarasota, Florida, United States | Recruiting |
+ 140 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05671510